Your browser doesn't support javascript.
loading
A novel copper chelator for the suppression of colorectal cancer.
Shi, Xiaolong; Li, Ying; Jia, Mengting; Zhang, Zhixin; Huang, Lunhua; Zhang, Miaomiao; Xun, Qingqing; Jiang, Di; Liu, Yanrong.
Afiliação
  • Shi X; Medical Research Center, Affiliated Hospital of Jining Medical University, Jining, Shandong, China.
  • Li Y; Postdoctoral Mobile Station of Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China.
  • Jia M; Medical Research Center, Affiliated Hospital of Jining Medical University, Jining, Shandong, China.
  • Zhang Z; Medical Research Center, Affiliated Hospital of Jining Medical University, Jining, Shandong, China.
  • Huang L; Department of Gastrointestinal Surgery, Affiliated Hospital of Jining Medical University, Jining, Shandong, China.
  • Zhang M; Department of Gastrointestinal Surgery, Affiliated Hospital of Jining Medical University, Jining, Shandong, China.
  • Xun Q; Medical Research Center, Affiliated Hospital of Jining Medical University, Jining, Shandong, China.
  • Jiang D; Medical Research Center, Affiliated Hospital of Jining Medical University, Jining, Shandong, China.
  • Liu Y; Department of Pathology, Affiliated Hospital of Jining Medical University, Jining, Shandong, China.
Drug Dev Res ; 84(2): 312-325, 2023 04.
Article em En | MEDLINE | ID: mdl-36658741
ABSTRACT
Copper ions play a crucial role in the progression of cancers. Tumor tissue is rich in copper ions, and copper chelators could potentially scavenge these copper ions and thus exert an antitumor effect. In this study, we report the synthesis of a novel thieno[3,2-c]pyridine compound we have called "JYFY-001" that can act as the copper chelator thanks to the inclusion of an N-(pyridin-2-yl)acetamide moiety that targets copper ions. JYFY-001 potently inhibited cancer proliferation, inducing cell apoptosis and impairing the extracellular acidification rate and oxygen consumption rate of colorectal cancer (CRC) cells. JYFY-001 also inhibited the growth of a CRC-transplanted tumor in a dose-dependent manner, inducing apoptosis of the tumor cells and promoting the infiltration of lymphocytes in the CRC-transplanted tumor tissues. JYFY-001 also enhanced the antitumor effects of the programmed cell death protein 1 (PD-1) inhibitor. The relatively benign nature of JYFY-001 was demonstrated by the effect on normal cell viability and acute toxicity tests in mice. Our findings suggest that JYFY-001 is a prospective copper chelator to be used as a targeted drug and a synergist of immunotherapy for CRC treatments.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Cobre Tipo de estudo: Observational_studies Limite: Animals Idioma: En Revista: Drug Dev Res Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Cobre Tipo de estudo: Observational_studies Limite: Animals Idioma: En Revista: Drug Dev Res Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China